Table 1 Clinical characteristics of studied patients
From: Reduced expression of miR-146a in human bronchial epithelial cells alters neutrophil migration
Characteristic | All asthmatics | Eosinophilica phenotype | Neutrophilicb phenotype | Paucigranulocyticc phenotype | Controls |
|---|---|---|---|---|---|
n, (%) | 30 (100) | 11 (36.7) | 7 (23.3) | 12 (40.0) | 11 (100) |
Gender: male/female | 16/14 | 4/7 | 5/2 | 7/5 | 7/4 |
Age (y), mean ± SD | 45.6 ± 13.1 | 39.8 ± 9.5 | 48.1 ± 18.7 | 49.3 ± 11.3 | 52.2 ± 16.6 |
Duration of asthma (y), mean ± SD | 15.0 ± 16.3 | 8.3 ± 8.0 | 13.9 ± 7.9 | 21.8 ± 22.7 | NA |
FEV1 % predicted | 81.8 ± 24.0 | 86.6 ± 22.7 | 74.2 ± 32.9 | 81.9 ± 20.1 | 111.2 ± 9.6 |
FEV1 % reversibility | 7.2 ± 7.2 | 6.5 ± 5.4 | 6.2 ± 5.7 | 8.4 ± 9.5 | 3.0 ± 3.5 |
Positive skin prick test with common allergens n, (%) | 15 (50.0) | 4 (36.4) | 4 (57.1) | 7 (58.3) | NA |
Severity of asthma, median (IQR)d | 4 (1–5) | 4 (2–4) | 4 (2–5) | 4 (1–5) | NA |
Inhaled glucocorticosteroids (%, average dose μg, [range]) | 96.6, 969 (0–4000) | 100, 940 (250–2000) | 100, 929 (500–2000) | 91.6, 1020 (0–4000) | 0 |
Systemic glucocorticosteroids n, (%) | 7 (23.3) | 1 (9.1) | 4 (57.1) | 2 (16.7) | 0 |